Abstract
Objective
Ganciclovir is commonly used in the treatment of cytomegalovirus (CMV) disease in patients who are immunocompromised and for the prevention of CMV disease in solid organ transplant recipients. Owing to limited bioavailability and saturable absorption, the use of oral ganciclovir in CMV retinitis is restricted to maintenance therapy only. As induction therapy must be given intravenously, an oral formulation which could be used for induction would offer significant benefits. A previous study of valganciclovir, a valyl ester prodrug of ganciclovir showed a 10-fold increase in plasma ganciclovir concentrations compared with the oral formulation. However, before studies can be conducted to confirm the utility of oral valganciclovir for the treatment and prevention of CMV disease, a dose must be selected for use in these studies. This study was designed to investigate the pharmacokinetics of ganciclovir and valganciclovir.
Design and Participants
The study was an open-label, randomised, 4-way crossover, dose-ranging pharmacokinetic study, conducted in 39 patients who were HIV- and CMV-seropositive. The participants were randomised to one of 2 groups: fasted (n = 19) and fed (n = 20). In both groups, participants received 450, 875, 1750 and 2625mg oral valganciclovir once daily for 3 days in a randomised order.
Results
In the 32 participants who completed the study, valganciclovir was rapidly absorbed and converted into ganciclovir (maximum ganciclovir concentrations occurred after 1.0 to 1.75 hours in the fasted group and 1.5 to 2.0 hours in the fed group). Systemic exposure to valganciclovir was low [with an area under the concentration-time curve to 24 hours (AUC24) of 1.3 to 2.5% that of ganciclovir]. The mean plasma concentrations of ganciclovir were dose-related. Peak concentrations of ganciclovir were achieved approximately 30 minutes after those for valganciclovir. In the fed state, the AUC24 of ganciclovir increased proportionally with dose.
The mean AUC24 values for ganciclovir were slightly higher following food (24 to 56%) than in the fasted state. Based on linear regression of AUC24 values from the fed group, a dose of valganciclovir of 900 mg/day is expected to produce a daily expo sure (AUC24) comparable with an intravenous dose of ganciclovir 5 mg/kg/day.
Conclusions
These results show that once daily oral valganciclovir can produce exposures of ganciclovir (AUC24) exceeding those attained using intravenous ganciclovir 10 mg/kg. This suggests that oral valganciclovir may be suitable in many circumstances currently requiring intravenous ganciclovir, allowing for more convenience in the management of patients with CMV retinitis by utilising a 2 or 4 tablet daily regimen to cover all phases of treatment.
Similar content being viewed by others
References
Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992; 14: 608–15.
Polis MA, Masur H. Cytomegalovirus infection in patients with HIV infection. In: Broder S, Merigan TC, Bolognesi D, editors. Text book on AIDS medicine. Baltimore: Williams & Wilkins, 1994: 359–71.
Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993; 25 Suppl. 4: 15–21.
Holland GN, Sidikaro Y, Kreiger AE, et al. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 1987; 94: 815–23.
Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75–80.
Murray BM. Management of cytomegalovirus infection in solid-organ transplant recipients. Immunol Invest 1997; 26: 243–55.
Follansbee S, Busch D, Connor J, et al. Phase I study of the safety and pharmacokinetics of oral ganciclovir [abstract no. F.B. 91]. Proceedings of the Sixth International Conference on AIDS; 1990 Jun 20–23: San Francisco. San Francisco: University of California, 1990. 6 (2): 112.
Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000 mg/day dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. Clin Ther 1995; 17: 425–32.
Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 1995; 333: 615–20.
Gane E, Saliba F, Valdecasas JC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729–33.
Dhillon B, Kamal A, Leen C. Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS. Int J STD AIDS 1998; 9: 227–30.
Jung D, Dorr A. Single dose pharmacokinetics of valganciclovir in HIV- and CMV-seropostive subjects. J Clin Pharmacol. In press.
Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetics, safety and antiviral profiles of oral ganciclovir in persons infected with Human Immunodeficiency Virus: A phase I/II study. J Infect Dis 1995; 171: 1431–7.
F. Hoffmann-La Roche, 1998. (Data on file).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, F., Banken, L., Saywell, K. et al. Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive Volunteers. Clin Pharmacokinet 37, 167–176 (1999). https://doi.org/10.2165/00003088-199937020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199937020-00005